BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahmmod S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, Gilissen LPL, Hoentjen F, Lutgens MWMD, Mahmmod N, van der Meulen-de Jong AE, Smits LJT, Tan ACITL, Oldenburg B, Fidder HH. Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izaa364. [PMID: 33538298 DOI: 10.1093/ibd/izaa364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Afzali A, Furtner D, Melsheimer R, Molloy PJ. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable. Adv Ther 2021;38:2077-93. [PMID: 33745111 DOI: 10.1007/s12325-021-01688-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin 2022;:1-33. [PMID: 35125053 DOI: 10.1080/03007995.2022.2037846] [Reference Citation Analysis]
3 Massimi D, Barberio B, Bertani L, Costa F, Ferronato A, Facchin S, Cardin R, Cingolani L, Casadei C, D'Incà R, Zingone F, Savarino EV. Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. Therap Adv Gastroenterol 2021;14:17562848211023384. [PMID: 34249147 DOI: 10.1177/17562848211023384] [Reference Citation Analysis]
4 Meijboom RW, Gardarsdottir H, Egberts TCG, Giezen TJ. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs 2021. [PMID: 34870802 DOI: 10.1007/s40259-021-00508-4] [Reference Citation Analysis]
5 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Patil SA, Bhat S, Limdi JK, Farraye FA, Cross RK. The Sincerest Form of Flattery? Biosimilars in Inflammatory Bowel Disease. Inflamm Bowel Dis 2022:izac048. [PMID: 35353189 DOI: 10.1093/ibd/izac048] [Reference Citation Analysis]